AU2013351542B2 - Individualized vaccines for cancer - Google Patents

Individualized vaccines for cancer Download PDF

Info

Publication number
AU2013351542B2
AU2013351542B2 AU2013351542A AU2013351542A AU2013351542B2 AU 2013351542 B2 AU2013351542 B2 AU 2013351542B2 AU 2013351542 A AU2013351542 A AU 2013351542A AU 2013351542 A AU2013351542 A AU 2013351542A AU 2013351542 B2 AU2013351542 B2 AU 2013351542B2
Authority
AU
Australia
Prior art keywords
ser
sequence
pro
gly
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013351542A
Other languages
English (en)
Other versions
AU2013351542A1 (en
Inventor
Christian BENDER
Jan DIEKMANN
Claudia PARET
Ugur Sahin
Kirsten VORMBROCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
BioNTech SE
Original Assignee
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, BioNTech SE filed Critical Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Publication of AU2013351542A1 publication Critical patent/AU2013351542A1/en
Application granted granted Critical
Publication of AU2013351542B2 publication Critical patent/AU2013351542B2/en
Priority to AU2018256508A priority Critical patent/AU2018256508B2/en
Priority to AU2020230292A priority patent/AU2020230292B2/en
Assigned to TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH, BioNTech SE reassignment TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH Request for Assignment Assignors: BIONTECH RNA PHARMACEUTICALS GMBH, TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
Priority to AU2024200226A priority patent/AU2024200226A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2013351542A 2012-11-28 2013-11-26 Individualized vaccines for cancer Active AU2013351542B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2018256508A AU2018256508B2 (en) 2012-11-28 2018-10-30 Individualized vaccines for cancer
AU2020230292A AU2020230292B2 (en) 2012-11-28 2020-09-10 Individualized vaccines for cancer
AU2024200226A AU2024200226A1 (en) 2012-11-28 2024-01-12 Individualized vaccines for cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12008007 2012-11-28
EP12008007.2 2012-11-28
PCT/EP2013/003559 WO2014082729A1 (en) 2012-11-28 2013-11-26 Individualized vaccines for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018256508A Division AU2018256508B2 (en) 2012-11-28 2018-10-30 Individualized vaccines for cancer

Publications (2)

Publication Number Publication Date
AU2013351542A1 AU2013351542A1 (en) 2015-06-11
AU2013351542B2 true AU2013351542B2 (en) 2018-08-09

Family

ID=47278643

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013351542A Active AU2013351542B2 (en) 2012-11-28 2013-11-26 Individualized vaccines for cancer
AU2018256508A Active AU2018256508B2 (en) 2012-11-28 2018-10-30 Individualized vaccines for cancer
AU2020230292A Active AU2020230292B2 (en) 2012-11-28 2020-09-10 Individualized vaccines for cancer
AU2024200226A Pending AU2024200226A1 (en) 2012-11-28 2024-01-12 Individualized vaccines for cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2018256508A Active AU2018256508B2 (en) 2012-11-28 2018-10-30 Individualized vaccines for cancer
AU2020230292A Active AU2020230292B2 (en) 2012-11-28 2020-09-10 Individualized vaccines for cancer
AU2024200226A Pending AU2024200226A1 (en) 2012-11-28 2024-01-12 Individualized vaccines for cancer

Country Status (6)

Country Link
US (3) US10155031B2 (cg-RX-API-DMAC7.html)
EP (3) EP3417874B1 (cg-RX-API-DMAC7.html)
JP (5) JP6484558B2 (cg-RX-API-DMAC7.html)
AU (4) AU2013351542B2 (cg-RX-API-DMAC7.html)
CA (1) CA2892391C (cg-RX-API-DMAC7.html)
WO (1) WO2014082729A1 (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013351542B2 (en) * 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
EP3194970B1 (en) 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
CA2977801C (en) 2015-02-26 2024-03-19 Sio2 Medical Products, Inc. Cycloolefin polymer container with a scratch resistant and anti-static coating
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
TW201708536A (zh) * 2015-05-26 2017-03-01 艾法西斯公司 個人化的基於遞送載體之免疫療法及其用途
CA3172801A1 (en) * 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
US11908588B2 (en) 2015-08-25 2024-02-20 Nantomics Llc Systems and methods for genetic analysis of metastases
KR20180087246A (ko) * 2015-10-12 2018-08-01 난토믹스, 엘엘씨 네오에피토프의 반복적 발견 및 이에 대한 적응성 면역치료 및 방법
EP3364949A4 (en) * 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
AU2017219901B2 (en) 2016-02-19 2022-07-14 Nant Holdings Ip, Llc Methods of immunogenic modulation
JP6710004B2 (ja) * 2016-03-15 2020-06-17 Repertoire Genesis株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
JP2019513021A (ja) * 2016-03-24 2019-05-23 ナントセル,インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
CN109328070A (zh) * 2016-05-04 2019-02-12 免疫疫苗技术有限公司 包含两亲化合物、新抗原和疏水载体的疫苗组合物及其使用方法
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
CA3061240C (en) 2017-04-24 2024-01-16 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
WO2018224166A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
AU2018287169B2 (en) * 2017-06-22 2024-11-14 Neogap Therapeutics Ab T-cell expansion method and uses
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) * 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
EP3784688A2 (en) 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
WO2020020444A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
BR112021005702A8 (pt) 2018-09-27 2022-11-08 Vaccibody As Método para selecionar neoepítopos
MA54192A (fr) * 2018-11-07 2021-09-15 Modernatx Inc Vaccins à arn contre le cancer
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN113396230A (zh) 2019-02-08 2021-09-14 豪夫迈·罗氏有限公司 癌症的诊断和治疗方法
CA3142339A1 (en) 2019-05-31 2020-12-03 Rubryc Therapeutics, Inc. Machine learning-based apparatus for engineering meso-scale peptides and methods and system for the same
CR20220330A (es) 2019-12-13 2022-08-04 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso.
US20230008870A1 (en) * 2019-12-20 2023-01-12 University Of Utah Research Foundation Methods and compositions for monitoring and diagnosing healthy and disease states
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
WO2021205027A1 (en) * 2020-04-09 2021-10-14 Vaccibody As Individualized therapeutic anticancer vaccine
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
KR20230086765A (ko) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
EP4046651A1 (en) * 2021-02-23 2022-08-24 baseclick GmbH Method for producing an mrna tumor vaccine
GB2623728A (en) * 2021-08-15 2024-04-24 R Burton Dennis Undirected mutated MRNA vaccine
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
CN114350800B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
CN117919389B (zh) * 2024-03-22 2024-07-23 上海南方模式生物科技股份有限公司 肿瘤新抗原dna疫苗
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2026096894A1 (en) 2024-11-01 2026-05-07 BioNTech SE Methods and systems for mass-spectrometry-based detection of non-canonical peptides
WO2026159255A1 (en) 2025-01-24 2026-07-30 BioNTech SE Technologies for mutation detection using tumor modeling and feedback

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
WO2012159754A2 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
EP0895538B1 (en) 1996-04-19 2002-07-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
DE69723434T2 (de) 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
EP0938298B1 (en) 1996-09-13 2002-12-04 Lipoxen Technologies Limited Liposome-based composition
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
WO1999024566A1 (en) 1997-11-06 1999-05-20 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
WO1999034015A2 (en) 1997-12-24 1999-07-08 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
JP2002526421A (ja) 1998-10-05 2002-08-20 ジェンザイム・コーポレーション 癌細胞に差別的に発現する癌ワクチン設計のための遺伝子
KR100773109B1 (ko) 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
EP1261704B1 (en) 1999-11-30 2009-07-01 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
AU780064B2 (en) 1999-12-28 2005-02-24 Epimmune, Inc. Optimized minigenes and peptides encoded thereby
EP1292331A2 (en) 2000-06-07 2003-03-19 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
EP1363938B1 (en) 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
ATE519115T1 (de) 2002-06-13 2011-08-15 Merck Patent Gmbh Verfahren für die identifizierung von allo- antigenen und ihre verwendung für krebstherapie und transplantation
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
WO2005039533A1 (en) 2003-10-15 2005-05-06 Medigene Ag Method of administering cationic liposomes comprising an active drug
BRPI0415533A (pt) 2003-10-24 2006-12-26 Immunaid Pty Ltd método de terapia
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
GB2434367B (en) * 2004-10-05 2010-05-12 Diversa Corp Improved vaccines
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
EP1838342A2 (en) 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2009532664A (ja) 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
JP2010504356A (ja) 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗b7−h1抗体を用いた癌及び感染性疾患の組合せ療法
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
CA2673870A1 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
KR101606219B1 (ko) 2008-03-24 2016-03-24 4에스체 악티엔게젤샤프트 신규 치환된 이미다조퀴놀린
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US20110195090A1 (en) * 2008-10-11 2011-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Method of making a vaccine
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
AU2010234362B2 (en) * 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
EA022786B1 (ru) 2009-07-31 2016-03-31 Этрис Гмбх Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
NZ616304A (en) * 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013106496A1 (en) 2012-01-10 2013-07-18 modeRNA Therapeutics Methods and compositions for targeting agents into and across the blood-brain barrier
WO2013124701A2 (en) 2012-02-20 2013-08-29 Universita' Degli Studi Di Milano New homo- and heterodimeric smac mimetic compounds as apoptosis inducers
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
MX364370B (es) 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
CA2890110C (en) 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
WO2014144711A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015038892A1 (en) 2013-09-13 2015-03-19 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
EP3049065A1 (en) 2013-09-26 2016-08-03 BioNTech AG Particles comprising a shell with rna
WO2015051173A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc Polynucleotide molecules and uses thereof
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
US20170173128A1 (en) 2013-12-06 2017-06-22 Moderna TX, Inc. Targeted adaptive vaccines
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170007776A1 (en) 2014-02-05 2017-01-12 Biontech Ag Cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
EP4023755B1 (en) 2014-12-12 2023-04-26 CureVac SE Artificial nucleic acid molecules for improved protein expression
BR112017009835A2 (pt) 2014-12-30 2017-12-26 Curevac Ag moléculas de ácido nucleico artificiais
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
WO2012159754A2 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOCCHIA M ET AL, "Antitumor vaccination: where we stand", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, FONDAZIONE FERRATA STORTI, ROME, IT, vol. 85, no. 11, pages 1172 - 1206 *
CASTLE JOHN C ET AL, "Exploiting the Mutanome for Tumor Vaccination", CANCER RESEARCH, (201203), vol. 72, no. 5, pages 1081 - 1091 *
GJERTSEN ET AL, "Mutated ras peptides as vaccines in immunotherapy of cancer", VOX SANGUINIS, S. KARGER AG, BASEL, CH, (19980101), vol. 74, no. 2, ISSN 0042-9007, pages 489 - 495 *
KREITER S ET AL, "Targeting the tumor mutanome for personalized vaccination therapy", ONCOIMMUNOLOGY 2012 LANDES BIOSCIENCE USA, (201208), vol. 1, no. 5, ISSN 2162-4011, pages 768 - 769 *
L. BUONAGURO ET AL, "Translating Tumor Antigens into Cancer Vaccines", CLINICAL AND VACCINE IMMUNOLOGY, (20110101), vol. 18, no. 1, doi:10.1128/CVI.00286-10, ISSN 1556-6811, pages 23 - 34 *
SRINIVASAN ROOPA ET AL, "Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, LONDON, GB, (20040416), vol. 2, no. 1, page 12 *

Also Published As

Publication number Publication date
JP7645616B2 (ja) 2025-03-14
AU2018256508A1 (en) 2018-11-22
JP2016501870A (ja) 2016-01-21
EP4483965A3 (en) 2025-04-02
AU2018256508B2 (en) 2020-11-26
US20160058853A1 (en) 2016-03-03
EP2925348A1 (en) 2015-10-07
WO2014082729A1 (en) 2014-06-05
AU2020230292B2 (en) 2024-02-15
AU2024200226A1 (en) 2024-02-01
JP2024081777A (ja) 2024-06-18
EP4483965A2 (en) 2025-01-01
WO2014082729A9 (en) 2014-07-10
EP3417874A1 (en) 2018-12-26
JP2026120709A (ja) 2026-07-22
CA2892391C (en) 2023-10-17
JP6484558B2 (ja) 2019-03-13
CA2892391A1 (en) 2014-06-05
JP2020200330A (ja) 2020-12-17
EP3417874B1 (en) 2024-09-11
EP2925348B1 (en) 2019-03-06
JP7851982B2 (ja) 2026-04-27
US20230190898A1 (en) 2023-06-22
US11504419B2 (en) 2022-11-22
AU2020230292A1 (en) 2020-10-01
AU2013351542A1 (en) 2015-06-11
JP6774479B2 (ja) 2020-10-21
US20190083593A1 (en) 2019-03-21
US10155031B2 (en) 2018-12-18
US12642844B2 (en) 2026-06-02
JP2019038837A (ja) 2019-03-14

Similar Documents

Publication Publication Date Title
AU2022201275B2 (en) Individualized vaccines for cancer
US20230190898A1 (en) Individualized vaccines for cancer
EP4223311B1 (en) Individualized vaccines for cancer
HK40120924A (en) Individualized vaccines for cancer
HK40098119B (en) Individualized vaccines for cancer
HK40098119A (en) Individualized vaccines for cancer
HK40006796A (en) Individualized vaccines for cancer
HK40006796B (en) Individualized vaccines for cancer
HK40052764A (en) Individualized vaccines for cancer
HK40000563A (en) Individualized vaccines for cancer
HK40000563B (en) Individualized vaccines for cancer
HK40052764B (en) Individualized vaccines for cancer
NZ617217B2 (en) Individualized vaccines for cancer
HK1191241B (en) Individualized vaccines for cancer
HK1191241A (en) Individualized vaccines for cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH

Free format text: FORMER OWNER(S): TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH; BIONTECH RNA PHARMACEUTICALS GMBH

Owner name: BIONTECH SE

Free format text: FORMER OWNER(S): TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH; BIONTECH RNA PHARMACEUTICALS GMBH